Associated Genetic Biomarkers
FGFR3 S371C is present in 0.01% of AACR GENIE cases, with bladder carcinoma, non-small cell lung carcinoma, and urothelial carcinoma having the greatest prevalence .
FGFR3 S371C serves as an inclusion eligibility criterion in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 S371C as an inclusion criterion, 1 is phase 1 (1 open).
Trials with FGFR3 S371C in the inclusion eligibility criteria most commonly target bladder carcinoma and urothelial carcinoma .
Significance of FGFR3 S371C in Diseases
Urothelial Carcinoma +
FGFR3 is mutated in 26.76% of urothelial carcinoma patients with FGFR3 S371C present in 0.15% of all urothelial carcinoma patients .
FGFR3 S371C is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 S371C and urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
Bladder Carcinoma +
FGFR3 is mutated in 24.07% of bladder carcinoma patients with FGFR3 S371C present in 0.08% of all bladder carcinoma patients .
FGFR3 S371C is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 S371C and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.